SG11202009466UA - Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives - Google Patents
Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivativesInfo
- Publication number
- SG11202009466UA SG11202009466UA SG11202009466UA SG11202009466UA SG11202009466UA SG 11202009466U A SG11202009466U A SG 11202009466UA SG 11202009466U A SG11202009466U A SG 11202009466UA SG 11202009466U A SG11202009466U A SG 11202009466UA SG 11202009466U A SG11202009466U A SG 11202009466UA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolo
- triazine
- pharmaceutically active
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656041P | 2018-04-11 | 2018-04-11 | |
| PCT/EP2019/059289 WO2019197546A1 (en) | 2018-04-11 | 2019-04-11 | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009466UA true SG11202009466UA (en) | 2020-10-29 |
Family
ID=66334384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009466UA SG11202009466UA (en) | 2018-04-11 | 2019-04-11 | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11858937B2 (en) |
| EP (1) | EP3774809A1 (en) |
| JP (2) | JP7406501B2 (en) |
| KR (1) | KR20200143429A (en) |
| CN (1) | CN112334471A (en) |
| AU (1) | AU2019250504B2 (en) |
| BR (1) | BR112020020645A2 (en) |
| CA (1) | CA3095426A1 (en) |
| IL (2) | IL299105B2 (en) |
| MX (1) | MX2020010563A (en) |
| PH (1) | PH12020551638A1 (en) |
| SG (1) | SG11202009466UA (en) |
| WO (1) | WO2019197546A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202146416A (en) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | Pyrazolotriazines |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| EP4255909A1 (en) | 2020-12-02 | 2023-10-11 | Qurient Co. Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
| WO2022248682A1 (en) * | 2021-05-28 | 2022-12-01 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) |
| WO2022266418A1 (en) * | 2021-06-17 | 2022-12-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023175173A1 (en) * | 2022-03-18 | 2023-09-21 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| WO2024028411A1 (en) | 2022-08-05 | 2024-02-08 | Qurient Co., Ltd. | Combination therapy of cdk7 inhibitors with other anti-cancer therapies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| EP2634189A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| AU2015240518A1 (en) * | 2014-04-05 | 2016-10-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| JP6789962B2 (en) | 2015-03-09 | 2020-11-25 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Pyrazolo [1,5-a] [1,3,5] triazine and pyrazolo [1,5-a] pyrimidine derivatives as CDK inhibitors |
| US20200197392A1 (en) | 2017-08-15 | 2020-06-25 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating tuberous sclerosis complex |
-
2019
- 2019-04-11 CA CA3095426A patent/CA3095426A1/en active Pending
- 2019-04-11 BR BR112020020645-8A patent/BR112020020645A2/en unknown
- 2019-04-11 US US17/045,009 patent/US11858937B2/en active Active
- 2019-04-11 EP EP19720424.1A patent/EP3774809A1/en active Pending
- 2019-04-11 SG SG11202009466UA patent/SG11202009466UA/en unknown
- 2019-04-11 KR KR1020207032377A patent/KR20200143429A/en unknown
- 2019-04-11 CN CN201980039675.8A patent/CN112334471A/en active Pending
- 2019-04-11 WO PCT/EP2019/059289 patent/WO2019197546A1/en active Application Filing
- 2019-04-11 AU AU2019250504A patent/AU2019250504B2/en active Active
- 2019-04-11 JP JP2020555188A patent/JP7406501B2/en active Active
- 2019-04-11 IL IL299105A patent/IL299105B2/en unknown
- 2019-04-11 MX MX2020010563A patent/MX2020010563A/en unknown
-
2020
- 2020-09-30 IL IL277694A patent/IL277694A/en unknown
- 2020-10-05 PH PH12020551638A patent/PH12020551638A1/en unknown
-
2023
- 2023-08-14 JP JP2023131905A patent/JP2023138859A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277694A (en) | 2020-11-30 |
| CN112334471A (en) | 2021-02-05 |
| AU2019250504A1 (en) | 2020-10-15 |
| MX2020010563A (en) | 2020-10-22 |
| BR112020020645A2 (en) | 2021-01-12 |
| US11858937B2 (en) | 2024-01-02 |
| IL299105B2 (en) | 2024-02-01 |
| EP3774809A1 (en) | 2021-02-17 |
| US20210139483A1 (en) | 2021-05-13 |
| CA3095426A1 (en) | 2019-10-17 |
| IL299105B1 (en) | 2023-10-01 |
| JP2023138859A (en) | 2023-10-02 |
| JP7406501B2 (en) | 2023-12-27 |
| AU2019250504B2 (en) | 2023-05-18 |
| KR20200143429A (en) | 2020-12-23 |
| WO2019197546A1 (en) | 2019-10-17 |
| JP2021521129A (en) | 2021-08-26 |
| IL299105A (en) | 2023-02-01 |
| PH12020551638A1 (en) | 2021-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277694A (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
| IL278171A (en) | Gip derivatives and uses thereof | |
| IL284835A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| EP3634430A4 (en) | Multibiotic agents and methods of using the same | |
| GB201711234D0 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives | |
| EP3802495A4 (en) | Heterocyclic derivatives and use thereof | |
| IL284994A (en) | Pyrrolopyrimidine derivative and use thereof | |
| SG11202010985TA (en) | Heterocyclic derivatives and use thereof | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| IL282527A (en) | Azaindazole-5 derivatives and their use | |
| EP3737676A4 (en) | Acetal compounds and therapeutic uses thereof | |
| PT3796975T (en) | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | |
| IL282526A (en) | Azaindazole-5 derivatives and their use | |
| IL274868A (en) | Imidazopyridine derivatives and the use thereof as medicament | |
| EP3805235A4 (en) | Halogenated biotin-modified dimer and use thereof | |
| EP3689431A4 (en) | Sheet-like shaped body and structure including same | |
| IL284843A (en) | Carbamate derivatives and uses thereof | |
| IL282142A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| EP4028502A4 (en) | N-acyl-tyrosine derivatives and uses thereof | |
| EP4069233A4 (en) | Pharmaceutical combination and use thereof | |
| IL292646A (en) | Pharmaceutical combination and use thereof | |
| EP4041744A4 (en) | 2-methoxyestradiol derivatives and medical uses thereof | |
| SI3732165T1 (en) | Peptide derivatives and therapeutic activity thereof | |
| GB201902087D0 (en) | Medicament and the use thereof | |
| EP3778612A4 (en) | Phosphate derivatives and use thereof |